News

How Matinas Biopharma Scores On My 5 C’s

Shares of Matinas Biopharma Holdings Inc. (MTNB) have performed extremely well over the past few months, up a whopping 365% since September 1, 2016. That kind of impressive move is representative of why investors are attracted to small-cap biopharma stocks. The right call can make you a lot of money in just a short period…

Can-Fite Phase 3 RA Program Ready To Start

Can-Fite Biopharma Ltd (NYSEMKT: CANF) is preparing to initiate a Phase 3 study with piclidenoson for the treatment of rheumatoid arthritis (RA) in the second quarter 2017. The Phase 3 study, called ACRobat, will investigate piclidenoson as a first line therapy and potential replacement for the current standard of care, methotrexate (MTX), in newly diagnosed…

Narcotic Bowel Syndrome An Intriguing Opportunity For Vitality Biopharma

Vitality Biopharma, Inc. (VBIO) is developing a new class of cannabinoid prodrugs, known as cannabosides, to overcome the limitations of raw Cannabis sativa or synthetic cannabinoids. It is a strategy I believe can create significant value due to the differentiation of cannaboside products from existing cannabinoids available through prescription or over-the-counter means. The strategy also effectively distinguishes Vitality…

Time To Go Long Brainstorm Cell Therapeutics?

BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease (PD). The company’s NurOwn® technology is based on the use of mesenchymal stem cells (MSCs), engineered ex vivo, to express increased amount of neurotrophic factors (NTFs)….

JPM Meeting Notes – VistaGen Therapeutics (VTGN)

I think VistaGen Therapeutics’ (VTGN) AV-101 is one of the more interesting small-cap biopharma assets in mid-stage development. I’ve written in the past that I think AV-101 has blockbuster sales potential. Heck, there was just a Reuters story out today talking about how large and open this market is. The drug is currently in a Phase 2a…

JPM Meeting Notes – MabVax Therapeutics (MBVX)

MabVax Therapeutics (MBVX) is another company I had a very opportunistic meeting with because they announced that morning the IND for MVT-1075 had been filed. If all goes smoothly, we should see MVT-1075 in the clinic in the second quarter 2017. Now we all know billions (if not trillions) of mice have been cured of cancer over…

JPM Meeting Notes – RedHill Biopharma (RDHL)

As expected, much of my meeting with RedHill Biopharma (RDHL) was focused on the company’s newly acquired rights to Donnatal® in certain areas of the U.S. Now I’ve been traveling for the past several days, so I have not had an opportunity yet to do a deep dive into Donnatal but what I do know is that…

JPM Meeting Notes – Matinas Biopharma (MTNB)

In my pervious commentary on Matinas Biopharma (MTNB) called the company one of my best ideas for 2017. That certainly did not change after my meeting with management. My conversations with the company focused on the ongoing warrant exchange and timelines for some of the very important ongoing clinical studies. To review, there are currently two Phase…

JPM Meeting Notes – InVivo Therapeutics (NVIV)

My meeting with InVivo Therapeutics (NVIV) was rather boring. We talked about the weather and Boston sports teams – not much to report. Just kidding! Obviously, enrollment was a primary topic of discussion. Management continues to believe that the pace will accelerate in the coming weeks and that full enrollment is probable by the end…

JPM Meeting Notes – Can-Fite Biopharma (CANF)

I picked a good day to meet with Can-Fite Biopharma (CANF) because that morning the company announced IRB approval from Hadassah Medical Center and Rabin Medical Center, two leading medical institutions in Israel, to commence patient enrollment in a Phase 2 study of namodenoson (formerly CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor…